

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

AUG - 4 2004

Ms. Peg Larson President SONOTECH, Inc. 774 Marine Drive BELLINGHAM WA 98225-1530 Re: K033178

Trade/Device Name: Ultrabio – InVivo Biocompatible, Bioeliminated Sterile Ultrasound Imaging Couplant

Regulation Number: 21 CFR 892.1570

Regulation Name: Diagnostic ultrasonic transducer

Regulatory Class: II Product Code: 90 MUI Dated: July 12, 2004 Received: July 20, 2004

Dear Ms. Larson:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of the letter:

8xx,1xxx	(301) 594-4591
876.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4616
884.2xxx, 3xxx, 4xxx, 5xxx, 6xxx	(301) 594-4616
892.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4654
Other	(301) 594-4692

Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Mancy C. Brogdon
Nancy C. Brogdon

Director, Division of Reproductive, Abdominal and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

		·		Page 7 or 19	
510(k) Number (f known):	K033178			
Device Name:	ULTRABIO -	- IN VIVO BIOCOMP	ATIBLE,	BIOELIMINATED STERILE ULTH IMAGING COUPLANT	RASOUND
Indications For U	se:				
-tarilized transcrutance	uie ecannino	nals that are not in	VIVO DIOC	couplant, is intended to replace ompatible or in vivo bioexcretable inilar sterile applications.	e, but
Annual Looks during into	aoperative a scutaneous	and intracavitary med a ultrasound image g	uided bio	nt and medical imaging electron nostic ultrasound imaging proce psy and aspiration, intraoperation	uurca.
UltraBio is unit dose	packaged, s ntly use an u thylene trans	terilized and intende	ed for use ael or fluid	in all diagnostic ultrasound d alone or in combination with a nd in vivo biocompatibility and	latex,
			•		
		•			
MI BAOD DO MO					
·				ANOTHER PAGE IF NEEDED)	
Co	ncurrence of	f CDRH, Office of D	evice Eva	luation (ODE)	÷
Prescription Use V (Per 21 CFR 801.10	9)	OR	(Over-The-Counter Use	
				(Optional Format 1-2-96)	
		(Division Sign-O	cyc ki	oglon_	
		Division of Repro and Radiological	ductive, Al Devices	odominal,	
		510(k) Number_	<u>K033</u>	3178	